Michael Alan Horberg

Summary

Affiliation: Kaiser Permanente
Country: USA

Publications

  1. ncbi Determination of optimized multidisciplinary care team for maximal antiretroviral therapy adherence
    Michael A Horberg
    Mid Atlantic Permanente Research Institute, Rockville, MD 20852, USA
    J Acquir Immune Defic Syndr 60:183-90. 2012
  2. ncbi CD4 count at presentation for HIV care in the United States and Canada: are those over 50 years more likely to have a delayed presentation?
    Keri N Althoff
    Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, 615 N Wolfe St, Baltimore, MD, 21205, USA
    AIDS Res Ther 7:45. 2010
  3. ncbi Development of national and multiagency HIV care quality measures
    Michael A Horberg
    HIV Interregional Initiative, Kaiser Permanente, Oakland, CA 94612, USA
    Clin Infect Dis 51:732-8. 2010
  4. ncbi Impact of tenofovir on renal function in HIV-infected, antiretroviral-naive patients
    Michael Horberg
    HIV Initiative, Kaiser Permanente, 2000 Broadway Oakland, CA 94612, USA
    J Acquir Immune Defic Syndr 53:62-9. 2010
  5. ncbi Syphilis epidemiology and clinical outcomes in HIV-infected and HIV-uninfected patients in Kaiser Permanente Northern California
    Michael A Horberg
    Division of Research, Kaiser Permanente Northern California, Oakland, CA, USA
    Sex Transm Dis 37:53-8. 2010
  6. ncbi Surgical outcomes in human immunodeficiency virus-infected patients in the era of highly active antiretroviral therapy
    Michael A Horberg
    Kaiser Permanente Medical Care Program Northern California, 2000 Broadway, Oakland, CA 94612, USA
    Arch Surg 141:1238-45. 2006
  7. ncbi Efficacy and safety of ritonavir-boosted and unboosted atazanavir among antiretroviral-naïve patients
    Michael Horberg
    HIV Initiative, Kaiser Permanente, Oakland, California 94612, USA
    HIV Clin Trials 9:367-74. 2008
  8. ncbi Influence of prior antiretroviral experience on adherence and responses to new highly active antiretroviral therapy regimens
    Michael Horberg
    Kaiser Permanente Medical Care Program Northern California Division of Research, Oakland, California, USA
    AIDS Patient Care STDS 22:301-12. 2008
  9. ncbi Effects of depression and selective serotonin reuptake inhibitor use on adherence to highly active antiretroviral therapy and on clinical outcomes in HIV-infected patients
    Michael Alan Horberg
    HIV Research, Kaiser Permanente, Oakland, CA 94612, USA
    J Acquir Immune Defic Syndr 47:384-90. 2008
  10. ncbi Effect of clinical pharmacists on utilization of and clinical response to antiretroviral therapy
    Michael Alan Horberg
    Division of Research, Kaiser Permanente Northern California, 2000 Broadway, Oakland, CA 94612, USA
    J Acquir Immune Defic Syndr 44:531-9. 2007

Collaborators

Detail Information

Publications16

  1. ncbi Determination of optimized multidisciplinary care team for maximal antiretroviral therapy adherence
    Michael A Horberg
    Mid Atlantic Permanente Research Institute, Rockville, MD 20852, USA
    J Acquir Immune Defic Syndr 60:183-90. 2012
    ..We seek to determine the optimized multidisciplinary care team (MDCT) composition for antiretroviral therapy (ART) adherence...
  2. ncbi CD4 count at presentation for HIV care in the United States and Canada: are those over 50 years more likely to have a delayed presentation?
    Keri N Althoff
    Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, 615 N Wolfe St, Baltimore, MD, 21205, USA
    AIDS Res Ther 7:45. 2010
    ..10%, respectively). Due to the increasing proportion, consistently lower CD4 counts, and more advanced HIV disease in adults ≥50-year-old at first presentation for HIV care, renewed HIV testing efforts are needed...
  3. ncbi Development of national and multiagency HIV care quality measures
    Michael A Horberg
    HIV Interregional Initiative, Kaiser Permanente, Oakland, CA 94612, USA
    Clin Infect Dis 51:732-8. 2010
    ..Human immunodeficiency virus (HIV) is now a complex, chronic disease requiring high quality care. Demonstration of quality HIV care requires uniform, aligned HIV care quality measurement...
  4. ncbi Impact of tenofovir on renal function in HIV-infected, antiretroviral-naive patients
    Michael Horberg
    HIV Initiative, Kaiser Permanente, 2000 Broadway Oakland, CA 94612, USA
    J Acquir Immune Defic Syndr 53:62-9. 2010
    ..To better characterize the long-term effects of tenofovir on renal function in a large managed care organization...
  5. ncbi Syphilis epidemiology and clinical outcomes in HIV-infected and HIV-uninfected patients in Kaiser Permanente Northern California
    Michael A Horberg
    Division of Research, Kaiser Permanente Northern California, Oakland, CA, USA
    Sex Transm Dis 37:53-8. 2010
    ..We describe differences between HIV-infected and HIV-uninfected patients diagnosed with syphilis within Kaiser Permanente Northern California...
  6. ncbi Surgical outcomes in human immunodeficiency virus-infected patients in the era of highly active antiretroviral therapy
    Michael A Horberg
    Kaiser Permanente Medical Care Program Northern California, 2000 Broadway, Oakland, CA 94612, USA
    Arch Surg 141:1238-45. 2006
    ..Matched patients who test positive or negative for human immunodeficiency virus (HIV) who are undergoing comparable operations have similar complication rates and outcomes...
  7. ncbi Efficacy and safety of ritonavir-boosted and unboosted atazanavir among antiretroviral-naïve patients
    Michael Horberg
    HIV Initiative, Kaiser Permanente, Oakland, California 94612, USA
    HIV Clin Trials 9:367-74. 2008
    ..Evaluate responses and safety of ritonavir-boosted atazanavir ("boosted atazanavir") compared to unboosted atazanavir among antiretroviral-naïve patients in the clinical managed care setting...
  8. ncbi Influence of prior antiretroviral experience on adherence and responses to new highly active antiretroviral therapy regimens
    Michael Horberg
    Kaiser Permanente Medical Care Program Northern California Division of Research, Oakland, California, USA
    AIDS Patient Care STDS 22:301-12. 2008
    ..These findings should help direct HAART adherence efforts in HIV care clinics...
  9. ncbi Effects of depression and selective serotonin reuptake inhibitor use on adherence to highly active antiretroviral therapy and on clinical outcomes in HIV-infected patients
    Michael Alan Horberg
    HIV Research, Kaiser Permanente, Oakland, CA 94612, USA
    J Acquir Immune Defic Syndr 47:384-90. 2008
    ..To determine the impact of depression on highly active antiretroviral therapy (HAART) adherence and clinical measures and investigate if selective serotonin reuptake inhibitors (SSRIs) improve these measures...
  10. ncbi Effect of clinical pharmacists on utilization of and clinical response to antiretroviral therapy
    Michael Alan Horberg
    Division of Research, Kaiser Permanente Northern California, 2000 Broadway, Oakland, CA 94612, USA
    J Acquir Immune Defic Syndr 44:531-9. 2007
    ..To determine the association of clinical pharmacists with health outcomes and utilization measures among HIV-infected patients...
  11. ncbi Race/ethnicity and risk of AIDS and death among HIV-infected patients with access to care
    Michael J Silverberg
    Division of Research, Kaiser Permanente Northern California, Oakland, CA 94612, USA
    J Gen Intern Med 24:1065-72. 2009
    ..Prior studies evaluating racial/ethnic differences in responses to antiretroviral therapy (ART) among HIV-infected patients have not adequately accounted for many potential confounders, and few have included Hispanic patients...
  12. ncbi HIV infection and the risk of cancers with and without a known infectious cause
    Michael J Silverberg
    Division of Research, Kaiser Permanente Northern California, 2000 Broadway, Oakland, CA 94612, USA
    AIDS 23:2337-45. 2009
    ..To evaluate the risk of cancers with and without a known infectious cause in HIV-infected persons...
  13. ncbi Older age and the response to and tolerability of antiretroviral therapy
    Michael J Silverberg
    Division of Research, Kaiser Permanente Northern California, 2000 Broadway, Oakland, CA 94612, USA
    Arch Intern Med 167:684-91. 2007
    ..The unique health needs of a growing older adult population infected with human immunodeficiency virus (HIV) require study, especially in terms of the response to and tolerability of highly active antiretroviral therapy (HAART)...
  14. ncbi Response to newly prescribed lipid-lowering therapy in patients with and without HIV infection
    Michael J Silverberg
    Kaiser Permanente Northern California, Oakland, California, USA
    Ann Intern Med 150:301-13. 2009
    ..Antiretroviral agents, particularly protease inhibitors (PIs), may adversely affect lipid levels in patients with HIV infection. However, it is not known whether HIV-associated dyslipidemia is more difficult to treat...
  15. ncbi Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection
    Gerd Fatkenheuer
    Universitätsklinik Köln, Cologne, Germany
    N Engl J Med 359:1442-55. 2008
    ....
  16. ncbi Maraviroc for previously treated patients with R5 HIV-1 infection
    Roy M Gulick
    Weill Cornell Medical College, New York, NY 10065, USA
    N Engl J Med 359:1429-41. 2008
    ..CC chemokine receptor 5 antagonists are a new class of antiretroviral agents...